FL S0348

Department of Health, in collaboration with the Board of Medicine, must conduct a study evaluating the therapeutic efficacy of 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and ketamine in treating mental health and medical conditions including depression, anxiety, PTSD, bipolar disorder, chronic pain, and migraines.

Study must evaluate whether alternative therapies are effective in treating the listed conditions and compare their efficacy to currently used treatments.

Department must submit a report of findings and recommendations for future legislative action to the Governor, President of the Senate, and Speaker of the House of Representatives by September 1, 2023.

Study authority expires September 30, 2023.

Effective date is July 1, 2022.